<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thehindu.com/news/cities/Hyderabad/drl-launches-doxercalciferol-injection-in-us/article30052802.ece"/>
    <meta property="og:site_name" content="The Hindu"/>
    <meta property="article:published_time" content="2019-11-22T14:50:00+00:00"/>
    <meta property="og:title" content="DRL launches Doxercalciferol injection in U.S."/>
    <meta property="og:description" content="Dr. Reddy’s Laboratories (DRL) has launched Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multiple-dose vials, in the U.S. market.A therapeutic generic equivalent of Hectorol (doxercalciferol) inje"/>
  </head>
  <body>
    <article>
      <h1>DRL launches Doxercalciferol injection in U.S.</h1>
      <address><time datetime="2019-11-22T14:50:00+00:00">22 Nov 2019, 14:50</time> by <a rel="author">Special Correspondent</a></address>
      <p>Dr. Reddy’s Laboratories (DRL) has launched Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multiple-dose vials, in the U.S. market.</p>
      <p>A therapeutic generic equivalent of Hectorol (doxercalciferol) injection, the product is approved by the U.S. Food and Drug Administration (USFDA).</p>
      <p>Announcing the launch on Friday, the Hyderabad-headquartered pharma major said the Hectorol injection brand and generics had U.S. sales of approximately $138 million MAT (moving annual turnover) for the 12 months ended September 2019. Hectorol is a trademark of Sanofi-Aventis US LLC and indicated for the treatment of secondary hyperparathyroidism (SHPT) patients with chronic kidney disease (CKD) on dialysis.</p>
    </article>
  </body>
</html>